XTL Biopharmaceuticals Ltd. (TLV:XTLB)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
4.800
0.00 (0.00%)
Apr 28, 2025, 5:24 PM IDT
-47.25%
Market Cap 43.19M
Revenue (ttm) 171.00K
Net Income (ttm) -3.93M
Shares Out 881.39M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 484,496
Average Volume 375,714
Open 5.000
Previous Close 4.800
Day's Range 4.800 - 5.000
52-Week Range 4.000 - 11.200
Beta 1.01
RSI 59.75
Earnings Date May 12, 2025

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and change... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 5
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol XTLB
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.